Supplementary Figure 4 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment

Supplementary Figure 4 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment

<p>Figure S4 shows the gating strategy of monocytes sorted from BAFF-expressing and control tumors</p>

Kaydedildi:

Detaylı Bibliyografya
Yazar:	Wei Liu (20030) (author)
Diğer Yazarlar:	Paweł Stachura (8480817) (author), Haifeng C. Xu (7373933) (author), Renáta Váraljai (15194397) (author), Prashant Shinde (3707917) (author), Nikkitha Umesh Ganesh (15194400) (author), Matthias Mack (148002) (author), Anke Van Lierop (15194403) (author), Anfei Huang (461244) (author), Balamurugan Sundaram (440602) (author), Karl S. Lang (8444004) (author), Daniel Picard (14938665) (author), Ute Fischer (15194406) (author), Marc Remke (3508145) (author), Bernhard Homey (31953) (author), Alexander Roesch (2416078) (author), Dieter Häussinger (15194409) (author), Philipp A. Lang (7373936) (author), Arndt Borkhardt (2891) (author), Aleksandra A. Pandyra (8444013) (author)
Baskı/Yayın Bilgisi:	2025
Konular:	Cancer Tumor Biology Immuno-oncology Immunology Cytokines Myeloid-derived suppressor cells NK cells Tumor immunology animal models Tumor-associated macrophages Skin Cancers Melanoma Tumor Microenvironment Cytokines and the microenvironment
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller

Supplementary Figure 1 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
Yazar:: Wei Liu (20030)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 2 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
Yazar:: Wei Liu (20030)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 3 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
Yazar:: Wei Liu (20030)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 5 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
Yazar:: Wei Liu (20030)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 6 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
Yazar:: Wei Liu (20030)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure7 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
Yazar:: Wei Liu (20030)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 1 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
Yazar:: Wei Liu (20030)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 2 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
Yazar:: Wei Liu (20030)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 3 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
Yazar:: Wei Liu (20030)
Baskı/Yayın Bilgisi: (2025)

Supplementary figures and tables FTS1 from Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial
Yazar:: Daniel S. Green (15047598)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figures SF1-SF9 from Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment
Yazar:: Robin M. Hallett (15037427)
Baskı/Yayın Bilgisi: (2025)

Supplementary Tables ST1-ST6 from Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment
Yazar:: Robin M. Hallett (15037427)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S1 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
Yazar:: Sonia A. Patel (15055688)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S2 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
Yazar:: Sonia A. Patel (15055688)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
Yazar:: Sonia A. Patel (15055688)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S4 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
Yazar:: Sonia A. Patel (15055688)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S5 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
Yazar:: Sonia A. Patel (15055688)
Baskı/Yayın Bilgisi: (2025)

Figure S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Yazar:: Dahihm Kim (16546203)
Baskı/Yayın Bilgisi: (2025)

Figure S2 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Yazar:: Dahihm Kim (16546203)
Baskı/Yayın Bilgisi: (2025)

Figure S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Yazar:: Dahihm Kim (16546203)
Baskı/Yayın Bilgisi: (2025)

Figure S4 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Yazar:: Dahihm Kim (16546203)
Baskı/Yayın Bilgisi: (2025)

Figure S5 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Yazar:: Dahihm Kim (16546203)
Baskı/Yayın Bilgisi: (2025)

Table S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Yazar:: Dahihm Kim (16546203)
Baskı/Yayın Bilgisi: (2025)

Table S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Yazar:: Dahihm Kim (16546203)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 1 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
Yazar:: Alexander N. Shoushtari (15023909)
Baskı/Yayın Bilgisi: (2025)

Supplementary video from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
Yazar:: Min Wu (14962986)
Baskı/Yayın Bilgisi: (2025)

Table S1 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
Yazar:: Min Wu (14962986)
Baskı/Yayın Bilgisi: (2025)

Table S2 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
Yazar:: Min Wu (14962986)
Baskı/Yayın Bilgisi: (2025)

Table S3 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
Yazar:: Min Wu (14962986)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figures from Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets
Yazar:: Defne Bayik (14961098)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Yazar:: Hansol Lee (15054787)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Yazar:: Hansol Lee (15054787)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Yazar:: Hansol Lee (15054787)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Yazar:: Hansol Lee (15054787)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
Yazar:: James S. Wilmott (15008931)
Baskı/Yayın Bilgisi: (2025)

Supplementary Tables S1-7 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
Yazar:: James S. Wilmott (15008931)
Baskı/Yayın Bilgisi: (2025)

Supplementary file 1_Single-cell transcriptomics identifies FOSL1-regulated IGFBP3+ melanoma subtype as a neuro-immunoregulatory signaling hub facilitating tumor progression.docx
Yazar:: Wenjia Ge (22687361)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
Yazar:: Jonathan M.J. Derry (16648337)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
Yazar:: Jonathan M.J. Derry (16648337)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
Yazar:: Jonathan M.J. Derry (16648337)
Baskı/Yayın Bilgisi: (2025)

Cannot write session to /tmp/vufind_sessions/sess_3385v8ff2ui9r08kcko2jrseh6